Disease Landscape and Forecast Insights

For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…

Squamous cell carcinoma of the head and neck (SCCHN)—one of the most commonly diagnosed cancers in China—has a dynamic drug development pipeline, including targeted and biomarker-driven…

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to several…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key NK/T-cell patient populations covering 171 countries and more than 99%…

Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…